Novartis Ag (NVS) 93.28 $NVS
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
Is It Time to Buy Hospira, Inc.'s Stock?
Leo Sun, The Motley Fool - Motley Fool - Mon Sep 08, 5:40PM CDT
Hospira , a maker of specialty injectable pharmaceuticals and medical devices, has had a great run over the past year, handily outperforming the market with a 39% rally during the past 12 months. Source: Ycharts After that big rally,...
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals
PR Newswire - Mon Sep 08, 9:00AM CDT
Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to 2023 forecast period. In 2013, five marketed TNF-alpha inhibitors dominated sales in the PsA market with over 90 percent of the $2.3 billion major-market total; adalimumab (AbbVie/Eisai's Humira) was the overall sales leader. Over the next decade, TNF-alpha inhibitors will retain their sales-leading position, but recently launched treatments ustekinumab (Janssen's Stelara) and apremilast (Celgene's Otezla), together with noval therapies--which include the anti-interleukin-17 monoclonal antibodies secukinumab (Novartis), ixekizumab (Eli Lilly), and brodalumab (Amgen/AstraZeneca/Kyowa Hakko Kirin) and the Janus-kinase inhibitor tofacitnib (Pfizer's Xeljanz)--will account for approximately 21 percent of 2023 PsA sales combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Merus Labs International Inc. Announces Acquisition of Sintrom(R)
Marketwire - Mon Sep 08, 7:32AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG ("Novartis" , in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom(R) (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom(R) has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired.
New Data presented at European Respiratory Society (ERS) comparing the once-daily dual bronchodilator Ultibro® Breezhaler® to Advair* Diskus* further supports the efficacy of Ultibro® Breezhaler® in moderate to severe COPD patients
CNW Group - Mon Sep 08, 7:00AM CDT
Novartis, announces today new data from the LANTERN study that demonstrated Ultibro(®) Breezhaler(® )(indacaterol/glycopyrronium bromide, QVA149) was superior in bronchodilation and rate of exacerbations vs Advair* Diskus* (salmeterol/fluticasone, (SFC)).(1) The head-to-head LANTERN study results were presented for the first time at the European Respiratory Society (ERS) International Congress, September 6-10, in Munich, Germany.
Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista(R)
Business Wire - Mon Sep 08, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This enrollment milestone payment from Novartis was triggered as a result of Ophthotech reaching the first enrollment goal under the agreement in its pivotal, multi-national Fovista(R) Phase 3 clinical program and is the first of a total of $130 million in potential enrollment-based milestones under the agreement. Fovista(R), Ophthotech's anti-platelet-derived growth factor (PDGF) compound, is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of wet AMD.
3 Reasons Sanofi's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 6:30AM CDT
Like almost all Big Pharmas, French biopharma Sanofi has had a number of key drugs lose patent protection over the last few years, resulting in a massive drop in earnings and revenue. Consequently, its shares have under-performed both the broader...
Why Is Novartis Investing in This $49 Billion Market?
Leo Sun, The Motley Fool - Motley Fool - Sun Sep 07, 5:03PM CDT
Novartis is primarily known as a pharmaceutical company, but it has recently made some interesting investments in the mobile health market. That is a smart long-term move, since the global mobile health market is expected to grow from $1.95...
Novartis data at ERS 2014 show once-daily Ultibro(R) Breezhaler(R) is superior in reducing COPD flare ups compared to Seretide(R)*
Thomson Reuters ONE - Sun Sep 07, 6:01AM CDT
Novartis International AG / Novartis data at ERS 2014 show once-daily Ultibro(R) Breezhaler(R) is superior in reducing COPD flare ups compared to Seretide(R)* . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Novartis AG for its ANDA Everolimus Oral Tablets (Zortress®)
PR Newswire - Fri Sep 05, 11:00AM CDT
Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for Everolimus oral tablets, 0.25 mg, 0.5 mg, and 0.75 mg, a generic version of Zortress® by Novartis AG. On August 13, 2014, Novartis AG filed a lawsuit against Breckenridge in the United States District Court for the District of Delaware. Breckenridge submitted its Paragraph IV ANDA on the First-to-File date and expects to be the only generic that is entitled to the 180-day exclusivity period. Breckenridge's development partner, Natco Pharma Limited, will commercially manufacture this ANDA exclusively for Breckenridge.
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
Novartis Offers Healthy Gains at a Bargain Stock Price
at The Street - Fri Sep 05, 5:30AM CDT
The company has a potential life-saving catalyst in its portfolio, too.
Future Horizons and Growth Strategies in the European Blood Banking Market 2014
M2 - Fri Sep 05, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fc9mp/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the European Blood Banking Market 2014: Supplier Shares and Country Forecasts" report to their offering. "2014 Opportunities in the European Blood Banking Market" is a new five-country strategic analysis prepared by the author in order to help current suppliers and potential market entrants identify and evaluate emerging opportunities and assist industry executives in developing effective business, new product development and marketing strategies. During the next five years, the European blood banking market is expected to undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations; advances in diagnostic technologies, IT, system engineering and automation; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and differentiation are more critical than underlying technology. The changes in the marketplace will create exciting opportunities for new instruments and reagent systems, as well as auxiliary products, such as specimen preparation devices, controls, calibrators, and innovative IT applications. Strategic Recommendations - New product development opportunities with significant market appeal. - Alternative market penetration strategies. - Potential market entry barriers and risks. Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Alternative Market Penetration Strategies IV. Potential Market Entry Barriers and Risks V. Worldwide Technology and Market Overview VI. France A. Executive Summary VII. Germany A. Executive Summary VIII. Italy A. Executive Summary IX. Spain A. Executive Summary X. U.K. A. Executive Summary XI. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Diagast - DiaSorin - Fujirebio/Innogenetics - Hologic/Gen-Probe - Grifols - Immucor - Novartis Diagnostics - Ortho-Clinical Diagnostics - Orchid CellMark - Proteome Sciences - Quest Diagnostics - Quidel - Roche - Siemens - Tecan For more information visit http://www.researchandmarkets.com/research/8f...e_horizons
Global Intranasal Drug Delivery Market & Pipeline Insight 2014: Powder, Gels, Liquid & Pressurized MDI
M2 - Thu Sep 04, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5232vq/global_intranasal) has announced the addition of the "Global Intranasal Drug Delivery Market & Pipeline Insight" report to their offering. Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral. The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies. With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies. The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route. Key Topics Covered: 1. Introduction to Intranasal Drug Delivery 2. Intranasal Drug Delivery Mechanism 3. Need for Intranasal Drug Delivery 4. Applications of Intranasal Drug Delivery 5. Intranasal Drug Delivery Market Overview 6. Intranasal Drug Delivery Market Dynamics 7. Intranasal Drug Delivery Market Future Outlook 8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country 9. Marketed Intranasal Drugs by Indication, Company & Country 10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country 11. Competitive Landscape - Aegis Therapeutics - Archimedes Pharma - GlaxoSmithKline - MEDA AB - MedImmune - Merck - NanoBio Corporation - Novartis - OptiNose - Pherin Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/52...intranasal
Delta and Office Depot are big market movers
AP - Wed Sep 03, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Array BioPharma To Present At The Morgan Stanley 2014 Global Healthcare Conference
PR Newswire - Wed Sep 03, 3:13PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley 2014 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
North America Anticoccidial Drugs Market - Global Trends And Forecasts 2014-2019
M2 - Wed Sep 03, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fprfmz/north_america) has announced the addition of the "North America Anticoccidial Drugs Market - Global Trends And Forecasts - (2014-19)" report to their offering. North American countries combined contribute around 24% of the global market for anticoccidial drugs. The demand for anticoccidial drugs is expected to grow by CAGR of 3.4 percent in terms of revenues by 2020. A majority of this is being driven by the prophylactic usage of anticoccidials in animal feed. Another factor driving the sales of anticoccidials is the increasing intake of meat. Demand for meat based food products is expected to go up as the cost of production of feed crops increases. The US is the most major market for anti coccidials in North America accounting for a lion's share of the market. Mexico follows a distant second and Canada third being driven mostly by the import from the US market. Key Topics Covered: 1 Introduction 2 Market Defenition 3 Market Drivers 4 Market Restraints 5 Market opportunities 6 Anti Coccidial drugs 7. Country wise analysis of anticoccidial market ( Market size, Forecast and CAGR) 8. Segmentation by Animal Type - North America anticoccidial market ( Market size, Forecast and CAGR) 9. The future of anticoccidial market 10. Competitive Landscape 11 Company Profiles - Zoetis - Smartvet Inc - Biopredic - Novartis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/fp...th_america
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
Is It Time to Buy Hospira, Inc.'s Stock?
Leo Sun, The Motley Fool - Motley Fool - Mon Sep 08, 5:40PM CDT
Hospira , a maker of specialty injectable pharmaceuticals and medical devices, has had a great run over the past year, handily outperforming the market with a 39% rally during the past 12 months. Source: Ycharts After that big rally,...
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals
PR Newswire - Mon Sep 08, 9:00AM CDT
Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to 2023 forecast period. In 2013, five marketed TNF-alpha inhibitors dominated sales in the PsA market with over 90 percent of the $2.3 billion major-market total; adalimumab (AbbVie/Eisai's Humira) was the overall sales leader. Over the next decade, TNF-alpha inhibitors will retain their sales-leading position, but recently launched treatments ustekinumab (Janssen's Stelara) and apremilast (Celgene's Otezla), together with noval therapies--which include the anti-interleukin-17 monoclonal antibodies secukinumab (Novartis), ixekizumab (Eli Lilly), and brodalumab (Amgen/AstraZeneca/Kyowa Hakko Kirin) and the Janus-kinase inhibitor tofacitnib (Pfizer's Xeljanz)--will account for approximately 21 percent of 2023 PsA sales combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Merus Labs International Inc. Announces Acquisition of Sintrom(R)
Marketwire - Mon Sep 08, 7:32AM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL)(NASDAQ: MSLI) is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG ("Novartis" , in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom(R) (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom(R) has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired. New Data presented at European Respiratory Society (ERS) comparing the once-daily dual bronchodilator Ultibro® Breezhaler® to Advair* Diskus* further supports the efficacy of Ultibro® Breezhaler® in moderate to severe COPD patients
CNW Group - Mon Sep 08, 7:00AM CDT
Novartis, announces today new data from the LANTERN study that demonstrated Ultibro(®) Breezhaler(® )(indacaterol/glycopyrronium bromide, QVA149) was superior in bronchodilation and rate of exacerbations vs Advair* Diskus* (salmeterol/fluticasone, (SFC)).(1) The head-to-head LANTERN study results were presented for the first time at the European Respiratory Society (ERS) International Congress, September 6-10, in Munich, Germany.
Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista(R)
Business Wire - Mon Sep 08, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This enrollment milestone payment from Novartis was triggered as a result of Ophthotech reaching the first enrollment goal under the agreement in its pivotal, multi-national Fovista(R) Phase 3 clinical program and is the first of a total of $130 million in potential enrollment-based milestones under the agreement. Fovista(R), Ophthotech's anti-platelet-derived growth factor (PDGF) compound, is being studied in combination with anti-vascular endothelial growth factor (VEGF) therapy for the treatment of wet AMD.
3 Reasons Sanofi's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 6:30AM CDT
Like almost all Big Pharmas, French biopharma Sanofi has had a number of key drugs lose patent protection over the last few years, resulting in a massive drop in earnings and revenue. Consequently, its shares have under-performed both the broader...
Why Is Novartis Investing in This $49 Billion Market?
Leo Sun, The Motley Fool - Motley Fool - Sun Sep 07, 5:03PM CDT
Novartis is primarily known as a pharmaceutical company, but it has recently made some interesting investments in the mobile health market. That is a smart long-term move, since the global mobile health market is expected to grow from $1.95...
Novartis data at ERS 2014 show once-daily Ultibro(R) Breezhaler(R) is superior in reducing COPD flare ups compared to Seretide(R)*
Thomson Reuters ONE - Sun Sep 07, 6:01AM CDT
Novartis International AG / Novartis data at ERS 2014 show once-daily Ultibro(R) Breezhaler(R) is superior in reducing COPD flare ups compared to Seretide(R)* . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Novartis AG for its ANDA Everolimus Oral Tablets (Zortress®)
PR Newswire - Fri Sep 05, 11:00AM CDT
Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for Everolimus oral tablets, 0.25 mg, 0.5 mg, and 0.75 mg, a generic version of Zortress® by Novartis AG. On August 13, 2014, Novartis AG filed a lawsuit against Breckenridge in the United States District Court for the District of Delaware. Breckenridge submitted its Paragraph IV ANDA on the First-to-File date and expects to be the only generic that is entitled to the 180-day exclusivity period. Breckenridge's development partner, Natco Pharma Limited, will commercially manufacture this ANDA exclusively for Breckenridge.
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
Novartis Offers Healthy Gains at a Bargain Stock Price
at The Street - Fri Sep 05, 5:30AM CDT
The company has a potential life-saving catalyst in its portfolio, too.
Future Horizons and Growth Strategies in the European Blood Banking Market 2014
M2 - Fri Sep 05, 3:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fc9mp/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the European Blood Banking Market 2014: Supplier Shares and Country Forecasts" report to their offering. "2014 Opportunities in the European Blood Banking Market" is a new five-country strategic analysis prepared by the author in order to help current suppliers and potential market entrants identify and evaluate emerging opportunities and assist industry executives in developing effective business, new product development and marketing strategies. During the next five years, the European blood banking market is expected to undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations; advances in diagnostic technologies, IT, system engineering and automation; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and differentiation are more critical than underlying technology. The changes in the marketplace will create exciting opportunities for new instruments and reagent systems, as well as auxiliary products, such as specimen preparation devices, controls, calibrators, and innovative IT applications. Strategic Recommendations - New product development opportunities with significant market appeal. - Alternative market penetration strategies. - Potential market entry barriers and risks. Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Alternative Market Penetration Strategies IV. Potential Market Entry Barriers and Risks V. Worldwide Technology and Market Overview VI. France A. Executive Summary VII. Germany A. Executive Summary VIII. Italy A. Executive Summary IX. Spain A. Executive Summary X. U.K. A. Executive Summary XI. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Diagast - DiaSorin - Fujirebio/Innogenetics - Hologic/Gen-Probe - Grifols - Immucor - Novartis Diagnostics - Ortho-Clinical Diagnostics - Orchid CellMark - Proteome Sciences - Quest Diagnostics - Quidel - Roche - Siemens - Tecan For more information visit http://www.researchandmarkets.com/research/8f...e_horizons
Global Intranasal Drug Delivery Market & Pipeline Insight 2014: Powder, Gels, Liquid & Pressurized MDI
M2 - Thu Sep 04, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5232vq/global_intranasal) has announced the addition of the "Global Intranasal Drug Delivery Market & Pipeline Insight" report to their offering. Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral. The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies. With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies. The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route. Key Topics Covered: 1. Introduction to Intranasal Drug Delivery 2. Intranasal Drug Delivery Mechanism 3. Need for Intranasal Drug Delivery 4. Applications of Intranasal Drug Delivery 5. Intranasal Drug Delivery Market Overview 6. Intranasal Drug Delivery Market Dynamics 7. Intranasal Drug Delivery Market Future Outlook 8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country 9. Marketed Intranasal Drugs by Indication, Company & Country 10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country 11. Competitive Landscape - Aegis Therapeutics - Archimedes Pharma - GlaxoSmithKline - MEDA AB - MedImmune - Merck - NanoBio Corporation - Novartis - OptiNose - Pherin Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/52...intranasal
Delta and Office Depot are big market movers
AP - Wed Sep 03, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Array BioPharma To Present At The Morgan Stanley 2014 Global Healthcare Conference
PR Newswire - Wed Sep 03, 3:13PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley 2014 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
North America Anticoccidial Drugs Market - Global Trends And Forecasts 2014-2019
M2 - Wed Sep 03, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fprfmz/north_america) has announced the addition of the "North America Anticoccidial Drugs Market - Global Trends And Forecasts - (2014-19)" report to their offering. North American countries combined contribute around 24% of the global market for anticoccidial drugs. The demand for anticoccidial drugs is expected to grow by CAGR of 3.4 percent in terms of revenues by 2020. A majority of this is being driven by the prophylactic usage of anticoccidials in animal feed. Another factor driving the sales of anticoccidials is the increasing intake of meat. Demand for meat based food products is expected to go up as the cost of production of feed crops increases. The US is the most major market for anti coccidials in North America accounting for a lion's share of the market. Mexico follows a distant second and Canada third being driven mostly by the import from the US market. Key Topics Covered: 1 Introduction 2 Market Defenition 3 Market Drivers 4 Market Restraints 5 Market opportunities 6 Anti Coccidial drugs 7. Country wise analysis of anticoccidial market ( Market size, Forecast and CAGR) 8. Segmentation by Animal Type - North America anticoccidial market ( Market size, Forecast and CAGR) 9. The future of anticoccidial market 10. Competitive Landscape 11 Company Profiles - Zoetis - Smartvet Inc - Biopredic - Novartis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/fp...th_america
